Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

August 6th 2024

A panel of experts offer future perspectives in HR+ breast cancer.

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

August 6th 2024

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

Dr Vahdat on Recent Data on ADCs in Metastatic TNBC

August 5th 2024

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.

Dr Gadi on Challenges in Identifying HER2-Low Breast Cancer in Community Settings

August 2nd 2024

VK Gadi, MD, PhD, discusses the challenge of identifying patients with HER2-low disease, emphasizing communication between pathologists and medical oncologists in the diagnostic process.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Ongoing Research Aims to Bring Novel TROP-2–Directed ADCs to Metastatic TNBC

July 31st 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.

Dr Lynce on the Prognosis of Patients With Inflammatory Breast Cancer

July 30th 2024

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

Bevacizumab Biosimilar Receives Approval in the European Union

July 30th 2024

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer

July 29th 2024

In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.

Future Directions and Unmet Needs in HR+ Breast Cancer

July 29th 2024

The key opinion leaders discuss the current unmet needs in the management of HR+/HER2- metastatic breast cancer and explore potential future directions and strategies that may lead to improved patient outcomes.

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

July 29th 2024

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

July 29th 2024

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

July 29th 2024

A panel of experts discuss navigating 2L treatment strategies.

Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

July 29th 2024

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

Unmet Needs and Future Direction in HER2+ Breast Cancer

July 29th 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

July 29th 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs

July 29th 2024

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC

July 28th 2024

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

July 26th 2024

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.